Skip to main content

Advertisement

Table 1 Demographics and clinical variables according to radiographic progression at the 24-month follow up

From: Self-reported flares are predictors of radiographic progression in rheumatoid arthritis patients in 28-joint disease activity score remission: a 24-month observational study

  All patients No radiographic progression Radiographic progression P valuea
Number 149 131 18  
 Age, years, mean (SD) 58.15 (12.58) 57.60 (12.71) 62.22 (11.01) 0.11
 Female, n (%) 123 (82.6) 108 (82.4) 15 (83.3) 0.61
 Disease duration, years, median (IQR) 13.00 (8.00; 21.00) 13.00 (8.00; 20.50) 13.50 (8.50; 30.75) 0.41
 Previous anti-TNFα failures, n (%) 30 (20.1) 26 (19.9) 4 (22.2) 0.51
 Positive ACPA and/or RF, n (%) 76 (51.0) 65 (49.6) 11 (61.1) 0.36
 Smokers or ex-smokers, n (%) 39 (26.2) 35 (26.7) 4 (22.2) 0.47
 TSS progression per year before baseline, median (IQR) 8.00 (5.00; 11.63) 7.32 (5.00; 11.10) 10.25 (7.38; 15.50) 0.02
 ADA treatments, n (%) 56 (37.6) 48 (36.6) 8 (44.4) 0.59
 ETA treatments, n (%) 93 (62.4) 83 (63.4) 10 (55.6) 0.59
 Low dose biologic, n (%) 103 (69.1) 89 (67.9) 14 (77.8) 0.40
 Concurrent DMARD use, n (%) 76 (51.0) 66 (50.4) 10 (55.6) 0.68
 PDN daily dose, mg, median (IQR) 1.00 (0.74; 2.00) 1.00 (0.60; 2.00) 1.50 (0.75; 2.00) 0.99
 TSS progression at the 24-month follow up, median (IQR) 0 (0) 0 (0) 2.00 (2.00; 14.00) <0.01
Baseline     
 HAQ, mean (SD) 0.74 (0.40) 0.73 (0.41) 0.87 (0.25) 0.08
 DAS28, median (IQR) 2.21 (1.92; 2.38) 2.24 (1.85; 2.38) 2.05 (2.05; 2.38) 0.53
 CRP, mg/L, median (IQR) 3.00 (1.00; 4.00) 3.00 (1.00; 4.00) 1.00 (1.00; 4.00) 0.24
 TJC, median (IQR) 1 (0; 2) 1 (0; 2) 1 (1; 1) 0.70
 SJC, median (IQR) 0 (0) 0 (0) 0 (0)
 Patient-VAS, mm, median (IQR) 20 (15; 20) 20 (10; 30) 20 (0) 0.23
Follow up, 24 months     
 HAQ, median (IQR) 0.74 (0.39) 0.73 (0.40) 0.85 (0.23) 0.18
 DAS28, median (IQR) 2.16 (1.80; 2.43) 2.18 (1.80; 2.63) 1.85 (1.82; 2.42) 0.52
 CRP, mg/L, median (IQR) 2.00 (1.00; 3.00) 2.00 (1.00; 3.00) 2.00 (2.00; 3.00) 0.29
 TJC, median (IQR) 1 (0; 2) 1 (0; 2) 0 (0; 1) 0.24
 SJC, median (IQR) 0 (0) 0 (0) 0 (0)
 Patient-VAS, mm, median (IQR) 20 (10; 30) 20 (10; 30) 33 (28; 35) 0.01
Change between baseline and 24-month follow up
 HAQ, median (IQR) 0 (−0.10; 0.07) 0 (−0.11; 0.07) 0.01 (−0.05; 0.05) 0.56
 DAS28, mean (SD) −0.13 (0.55) 0 (0.58) −0.02 (0.30) 0.63
 CRP, mg/L, median (IQR) 0 (−2.00; −2.00) 0 (−3.00; 2.00) 1.00 (−1.00; 1.00) 0.11
 TJC, median (IQR) 0 (−1; −1) 0 (−1; −1) −1 (−1; 0) 0.28
 SJC, median (IQR) 0 (0) 0 (0) 0 (0)
 Patient-VAS, mm, median (IQR) 5 (−5; 10) 0 (−10; 10) 13 (9; 15) <0.01
  1. SD standard deviation, IQR interquartile range, TNFα tumor necrosis factor-α, ACPA anti-citrullinated peptides, RF rheumatoid factor, TSS total Sharp score, ADA adalimumab, ETA etanercept, DMARD disease-modifying anti-rheumatic drug, PDN prednisone, HAQ Health Assessment Questionnaire, DAS28 disease activity score in 28 joints, CRP C-reactive protein, TJC tender joint count in 28 joints, SJC swollen joint count in 28 joints, patient-VAS patient’s global health measured on a visual analog scale. aUnpaired t test was used to compare variables with a normal distribution, Mann-Whitney test was used to compare variables with a non-normal distribution. Quantitative measures were compared using the chi-square test or Fisher’s exact test